Which trial do we need? Defining the optimal duration of antifungal therapy for invasive pulmonary aspergillosis
- Author(s)
- Desoubeaux, G; Mikulska, M; Lemaignen, A; Gyan, E; Stemler, J; Vanbiervliet, Y; Maertens, J; Lortholary, O; Paccoud, O; Slavin, MA; Cornely, OA; Neofytos, D; Lanternier, F;
- Details
- Publication Year 2026-05,Volume 32,Issue #5,Page 683-686
- Journal Title
- Clinical Microbiology and Infection
- Publication Type
- Commentary
- Publisher
- Elsevier
- Keywords
- Antifungal duration; Aspergillosis; Azole drugs; Curative therapy; Duration; Haematology; Isavuconazole; Posaconazole; Randomized clinical trial; Voriconazole
- Department(s)
- Infectious Diseases
- Publisher's Version
- https://doi.org/10.1016/j.cmi.2026.01.030
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2026-02-19 05:52:47
Last Modified: 2026-04-28 02:39:56